A new trading day began on Friday, with Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) stock price up 6.75% from the previous day of trading, before settling in for the closing price of $17.49. CNTA’s price has ranged from $6.15 to $18.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 1.99%. With a float of $89.08 million, this company’s outstanding shares have now reached $131.66 million.
Let’s determine the extent of company efficiency that accounts for 76 employees. In terms of profitability, gross margin is 89.52%, operating margin of -2342.65%, and the pretax margin is -2294.59%.
Centessa Pharmaceuticals plc ADR (CNTA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Centessa Pharmaceuticals plc ADR is 32.34%, while institutional ownership is 51.12%. The most recent insider transaction that took place on Dec 06 ’24, was worth 1,615,255. In this transaction Chief Executive Officer of this company sold 87,496 shares at a rate of $18.46, taking the stock ownership to the 575,661 shares. Before that another transaction happened on Dec 06 ’24, when Company’s Officer proposed sale 87,496 for $18.46, making the entire transaction worth $1,615,255.
Centessa Pharmaceuticals plc ADR (CNTA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.99% per share during the next fiscal year.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Here are Centessa Pharmaceuticals plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 21.52. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 355.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.55 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Looking closely at Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA), its last 5-days average volume was 0.5 million, which is a jump from its year-to-date volume of 0.42 million. As of the previous 9 days, the stock’s Stochastic %D was 70.39%. Additionally, its Average True Range was 1.02.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 98.98%, which indicates a significant increase from 97.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.61% in the past 14 days, which was lower than the 61.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.38, while its 200-day Moving Average is $12.22. However, in the short run, Centessa Pharmaceuticals plc ADR’s stock first resistance to watch stands at $19.08. Second resistance stands at $19.48. The third major resistance level sits at $20.20. If the price goes on to break the first support level at $17.96, it is likely to go to the next support level at $17.24. Now, if the price goes above the second support level, the third support stands at $16.84.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
With a market capitalization of 2.46 billion, the company has a total of 131,845K Shares Outstanding. Currently, annual sales are 6,850 K while annual income is -151,090 K. The company’s previous quarter sales were 0 K while its latest quarter income was -42,570 K.
